Silence Therapeutics (SLN) Prices 5.71M Share Offering at $21/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Silence Therapeutics Announces Oversubscribed $120 Million Private Placement
February 5, 2024 8:00 AM ESTLONDON--(BUSINESS WIRE)-- Silence Therapeutics plc (Nasdaq: SLN) (Silence or the Company), an experienced and innovative biotechnology company committed to transforming peoples lives by silencing diseases through precision engineered medicines, today announced an oversubscribed private placement of 5,714,286 of the Companys American Depositary Shares (ADSs)1 at a purchase price of US $21.00 per ADS, representing a premium of approximately 11% to Silences 30-day volume-weighted average price, with both new and existing institutional and accredited investors (the Private Placement). Silence anticipates that the aggregate gross proceeds of the Private Placement will be approximately US $120.0 million (approximately £94.6... More
